JZG03

JZG03 is a Category 1 innovative drug candidate developed by Jiangsu Jingze Biopharmaceutical for the treatment of fundus diseases, such as neovascular age-related macular degeneration (nAMD). As a Category 1 therapeutic under the National Medical Products Administration (NMPA) classification in China, JZG03 represents a new molecular entity that has not been previously approved globally. While the specific molecular target and mechanism of action remain undisclosed by the developer, the drug is a key component of Jingze's specialized ophthalmology pipeline, which also includes biosimilars for ranibizumab and aflibercept. This suggests that JZG03 likely targets pathways involved in ocular vascular dysfunction, such as the vascular endothelial growth factor (VEGF) or angiopoietin-2 (Ang-2) pathways. The candidate is currently in the preclinical stage of development.